Peptide Synthesis Methods: SPPS, LPPS, and Recombinant Production Explained

This article discusses peptide manufacturing methods for educational and scientific purposes. It does not provide guidance on producing peptides for human use. All synthesis information is intended for qualified research personnel.

Modern peptide synthesis encompasses three fundamental approaches: chemical synthesis (solid-phase and liquid-phase), biological production (recombinant expression), and chemo-enzymatic methods. The choice of synthesis strategy depends on peptide length, sequence complexity, required scale, post-translational modifications, and cost constraints. For research-grade peptides of 5-50 residues, solid-phase peptide synthesis (SPPS) using Fmoc chemistry dominates the field, accounting for the vast majority of custom peptide production. Longer sequences, proteins, or peptides requiring complex folding increasingly leverage recombinant expression systems or chemical ligation strategies.

Understanding synthesis methodology is relevant to peptide quality assessment because each method introduces characteristic impurity profiles. SPPS generates deletion sequences and truncation products; recombinant production may yield host-cell protein contaminants and incomplete processing; chemical ligation can leave auxiliary groups or produce hydrolyzed thioester byproducts. Awareness of these method-specific impurities informs analytical strategy and quality control expectations.

Fmoc (9-fluorenylmethyloxycarbonyl) SPPS is the most widely used method for research peptide production. The peptide is assembled C-to-N terminus on an insoluble polymeric resin support. Each synthesis cycle consists of four steps: (1) Fmoc removal from the alpha-amino group using 20% piperidine in DMF, generating a UV-active dibenzofulvene-piperidine adduct that enables real-time monitoring at 301 nm; (2) washing to remove deprotection byproducts; (3) coupling of the next Fmoc-protected amino acid using activation reagents such as HBTU/HOBt, HATU, or oxyma/DIC; and (4) washing to remove excess reagents.

Side chain protecting groups in Fmoc chemistry are acid-labile: tert-butyl (tBu) for Ser, Thr, Tyr, Asp, Glu; trityl (Trt) for Cys, His, Asn, Gln; Pbf for Arg; and Boc for Lys and Trp. Final global deprotection and resin cleavage use trifluoroacetic acid (TFA) cocktails containing scavengers (triisopropylsilane, water, ethanedithiol) to quench reactive cations generated during protecting group removal. Typical cleavage cocktails are TFA/TIS/H2O (95:2.5:2.5) for standard sequences.

Fmoc SPPS advantages include mild base-labile Fmoc removal (preserving acid-labile protecting groups), compatibility with automated synthesizers, real-time UV monitoring of deprotection efficiency, and a vast commercial selection of building blocks including non-natural amino acids. Practical length limits are approximately 50 residues before cumulative coupling inefficiency and side reactions produce unacceptable impurity levels. Difficult sequences containing aggregation-prone hydrophobic stretches, polyproline, or poly-Arg motifs may require pseudoproline dipeptides, backbone amide protection, or microwave-assisted synthesis to achieve acceptable crude purity.

Boc (tert-butyloxycarbonyl) SPPS was the original solid-phase method developed by Merrifield in 1963. The Boc group is removed by TFA (25-50% in DCM) in each deprotection cycle, with side chains protected by benzyl-based groups that are stable to TFA but cleaved by strong acids. Final cleavage uses anhydrous hydrogen fluoride (HF) or trifluoromethanesulfonic acid (TFMSA), requiring specialized Teflon-lined HF apparatus and significant safety infrastructure.

Despite its operational complexity, Boc SPPS retains advantages for specific applications. The in situ neutralization protocol developed by Kent and colleagues enables faster coupling kinetics than standard Fmoc protocols, and Boc chemistry produces fewer aspartimide-related side products for Asp-containing sequences because the benzyl ester side chain protection is more robust than the tBu ester used in Fmoc chemistry. Boc SPPS also generates less on-resin aggregation for certain hydrophobic sequences due to the use of more potent solvation conditions. However, the HF cleavage requirement has limited Boc SPPS primarily to specialized laboratories and large-scale manufacturing facilities.

Liquid-phase peptide synthesis (LPPS), also called solution-phase synthesis, assembles peptides in homogeneous solution without a solid support. Each coupling and deprotection step is followed by purification — typically extraction, crystallization, or chromatography — to remove excess reagents and byproducts. While more labor-intensive per residue than SPPS, LPPS offers key advantages: each intermediate can be fully characterized and purified to homogeneity, making it suitable for large-scale GMP production where regulatory requirements demand full intermediate characterization.

LPPS is particularly cost-effective for short peptides (2-10 residues) produced at multi-kilogram scale, where the fixed costs of resin-based SPPS become disproportionate. Fragment condensation approaches in LPPS assemble pre-purified peptide segments, reducing the number of chromatographic purification steps needed for the final product. The production of aspartame (Asp-Phe-OMe) and other commercial dipeptides relies on optimized LPPS routes, as does the manufacturing of several peptide active pharmaceutical ingredients including leuprolide and goserelin precursors.

Recombinant expression produces peptides through biological machinery: the target peptide gene is cloned into an expression vector, transformed into a host organism (typically E. coli, though yeast, insect cells, and mammalian cells are also used), and expressed as a fusion protein that is subsequently cleaved to release the target peptide. Common fusion partners include thioredoxin, SUMO, and maltose-binding protein, which enhance solubility and protect the peptide from intracellular proteolysis.

Recombinant production becomes economically favorable for peptides longer than approximately 40-50 residues, where chemical synthesis yields decline sharply. It is essential for producing peptides requiring complex disulfide patterns (as biological folding machinery can assist correct pairing), isotopically labeled peptides for NMR studies (using 13C/15N-enriched media), and peptides with genetically encoded non-canonical amino acids. Limitations include restriction to the 20 canonical amino acids (unless expanded genetic code systems are employed), potential for host cell protein and endotoxin contamination, incomplete leader sequence processing, and N-terminal methionine retention in bacterial expression systems.

Native chemical ligation (NCL), developed by Dawson, Muir, Clark-Lewis, and Kent in 1994, enables the chemoselective joining of two unprotected peptide segments in aqueous solution. The reaction requires a C-terminal thioester on one fragment and an N-terminal cysteine on the other. The mechanism proceeds through a transthioesterification intermediate, followed by a spontaneous S-to-N acyl shift that generates a native amide bond at the ligation junction.

NCL has revolutionized the chemical synthesis of proteins and large peptides. By assembling multiple SPPS-derived fragments (each within the 40-50 residue practical limit), NCL enables total chemical synthesis of targets exceeding 200 residues. Extensions of the original method include expressed protein ligation (EPL, combining recombinant intein-generated thioesters with synthetic peptides), desulfurization (converting the required junction Cys to Ala post-ligation), and auxiliary-mediated ligation for non-Cys junctions. The thioester component is typically prepared by Boc SPPS (direct thioester resin) or Fmoc SPPS with a thioester precursor such as an N-acylurea (Dawson Dbz linker) or hydrazide approach.

Convergent synthesis combines elements of SPPS, LPPS, and ligation chemistry to optimize the production of complex peptides. The target sequence is divided into fragments that are individually synthesized by SPPS, purified to high homogeneity, and then joined through fragment condensation (protected fragments in solution) or chemical ligation (unprotected fragments in aqueous conditions). This approach maximizes overall yield because purification at the fragment stage eliminates cumulative impurities that would otherwise propagate through a linear synthesis.

Hybrid strategies combining chemical synthesis and recombinant expression have emerged for producing semi-synthetic proteins. In these approaches, a large recombinant fragment is ligated to a synthetic fragment carrying specific modifications (non-natural amino acids, fluorescent labels, post-translational modification mimics) that cannot be introduced biologically. Sortase-mediated ligation and split-intein approaches provide enzymatic alternatives to NCL for fragment assembly, with the advantage of not requiring a Cys residue at the junction.

Method selection depends on a matrix of factors. For research-grade peptides at milligram scale (1-100 mg), Fmoc SPPS is almost universally the method of choice due to automation, speed, and broad building block availability. Cost per residue for standard Fmoc SPPS ranges from approximately USD 5-15 at research scale. For peptides exceeding 50 residues, NCL-based assembly of SPPS fragments or recombinant expression typically offers better economics and higher purity than attempting a single SPPS run.

At manufacturing scale (kilogram to metric ton), LPPS dominates for short peptides due to lower per-gram costs when resin and solvent expenses are amortized. Recombinant production becomes increasingly cost-competitive for longer peptides at large scale, particularly when the expression system is well-optimized and downstream purification is straightforward. The rise of GLP-1 receptor agonist manufacturing has driven significant investment in both chemical SPPS scale-up and recombinant production of peptides in the 30-40 residue range, with manufacturers pursuing both routes in parallel to secure supply chain redundancy.

Each synthesis method produces a characteristic impurity fingerprint. Fmoc SPPS crude material typically contains deletion peptides (from incomplete coupling), truncation sequences (from incomplete deprotection), and modification products (aspartimide from Asp residues, tBu adducts from incomplete scavenger quenching, TFA adducts). Boc SPPS impurity profiles include HF-mediated side reactions including alkylation of Trp, Met, and Cys residues by carbonium ions generated during cleavage.

Recombinant peptides may contain truncated forms from premature transcription termination, deamidated variants from the expression and purification process, and N-terminal methionine or signal peptide remnants. NCL products may contain hydrolyzed thioester, unreacted starting fragments, and desulfurization byproducts. Understanding these method-specific impurity profiles enables researchers to request appropriately targeted analytical data when sourcing peptides and to anticipate potential confounding species in their research assays.

• Read more: How to Verify Peptide Identity: Mass Spectrometry for Beginners → https://www.chemverify.com/learn/verify-peptide-identity-mass-spectrometry-beginners
• Read more: GMP Peptide Manufacturing: Standards and Quality Control Guidelines → https://www.chemverify.com/learn/gmp-peptide-manufacturing-standards-and-quality-control-guidelines
• Read more: Global Peptide Synthesis Market 2026: $1.9B Industry Report → https://www.chemverify.com/learn/peptide-market-2026-report
• Read more: SPPS Solid Phase Peptide Synthesis: Complete Guide for Researchers → https://www.chemverify.com/learn/spps-solid-phase-peptide-synthesis-complete-guide-for-researchers